Sympathetic effects and mediation: Sympathetic nerves inhibit insulin and stimulate glucagon secretion. Their activation may help mediate stress-induced changes in islet hormone secretion including the glucagon counterregulatory response to hypoglycemia.These effects may be mediated by the combination of the classical neurotransmitter noradrenaline and the sympathetic neuropeptides (galanin and NPY). All three neurotransmitters can inhibit insulin and stimulate glucagon secretion, thus mimicking the effects of sympathetic activation on islet hormone secretion. In addition, galanin and NPY meet several other of the criteria needed to be classified as a physiologic neurotransmitter.
Read More »Production Assistant, Diabetes In Control
What to Do If Metformin Fails To Get Patients To Target
Combination therapy resulting in superior glycemic control, weight loss versus either agent alone
Read More »New SGLT-2, Ertugliflozin Shows Promising Results for Diabetes Management
Ertugliflozin provides clinically significant reductions in blood glucose levels.
Read More »Combination of Insulin Glargine and Lixisenatide = LixiLan
A single, once-daily injection to lower both fasting and postprandial blood glucose
Read More »Identifying Treatment Intensification Patterns for Type 2 Patients with Poor Control
Are clinicians intensifying treatment before it is too late?
Read More »Incretin Therapy: Role in Gallbladder and Bile Duct Diseases
Initiation of glucagon like peptide-1 agonists may increase risk of gallbladder or bile duct disease and cholecystectomy; no increased risk associated with DPP-4 inhibitor therapy.
Read More »Transcript: Dr. Tim Garvey Part 2, Tools to Combat Obesity
In part 2 of this exclusive interview from AACE 2016, Dr. Garvey discusses the available tools -- medication, surgery, lifestyle interventions - to combat obesity, and which strategies are most effective.
Read More »Transcript: Dr. Tim Garvey Part 1, Clinical Practice Guidelines for Patients with Obesity
In part 1 of this exclusive interview from AACE 2016, Dr. Timothy Garvey discusses the new comprehensive clinical practice guidelines for patients with obesity.
Read More »Question #854
Please select the drug class that best fits the description. This shorter-acting insulin secretagogue may be associated with less hypoglycemia than the other secretagogues. 1. Biguanides 2. Sulfonylureas 3. Meglitinides 4. Thiazolidinediones Did you get it right? Follow the link to check your answer.
Read More »Aggressive Prediabetes Treatment
Should we be more aggressive for people with prediabetes and use more of the drugs we have available, rather than waiting until they progress to diabetes? Follow the link to share your opinion!
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.